Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

Thumbnail for Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

AML - 327

Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

Gautam Pantwalawalkar

Poster Presenter: Gautam Pantwalawalkar

Thumbnail for Psychiatric Manifestations of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy in Hematologic Malignancies: A Systematic Review and Meta-Analysis

CT - 328

Psychiatric Manifestations of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy in Hematologic Malignancies: A Systematic Review and Meta-Analysis

Anwesha Gupta

Poster Presenter: Anwesha Gupta

Thumbnail for Ruxolitinib Dose, Treatment-Emergent Transfusion Dependence, and Survival Outcomes in Myelofibrosis: Real-World Evidence From Taiwan

MPN - 331

Ruxolitinib Dose, Treatment-Emergent Transfusion Dependence, and Survival Outcomes in Myelofibrosis: Real-World Evidence From Taiwan

Tai-Chung Tseng

Poster Presenter: Tai-Chung Tseng

Thumbnail for Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

MCL - 332

Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

Ragav Vikraman Thiyagarajan

Poster Presenter: Ragav Vikraman Thiyagarajan

Thumbnail for Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

IBCL - 334

Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

Wenny Lin

Poster Presenter: Wenny Lin

Thumbnail for Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

AML - 336

Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

Tapan Giri

Poster Presenter: Tapan Giri

Thumbnail for Comparative Cardiovascular Safety of Ibrutinib, Acalabrutinib, and Zanubrutinib: A FAERS Disproportionality Analysis

CLL - 337

Comparative Cardiovascular Safety of Ibrutinib, Acalabrutinib, and Zanubrutinib: A FAERS Disproportionality Analysis

Alexander den Boef

Poster Presenter: Alexander den Boef

Thumbnail for Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

MM - 338

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani

Poster Presenter: Saad Z Usmani

Thumbnail for Trends in Mortality From Hodgkin & Non-Hodgkin Lymphoma in the United States, 1999-2024: A CDC WONDER Analysis

HL - 339

Trends in Mortality From Hodgkin & Non-Hodgkin Lymphoma in the United States, 1999-2024: A CDC WONDER Analysis

Allah Dad

Poster Presenter: Allah Dad

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.